Lifeward LTD

Lifeward Ltd. announced the appointment of Dr. Keith D. Rose as Chief Medical Officer, effective May 1, 2026, following his tenure in various medical affairs roles within the company.

Lifeward Ltd. announced its first quarter 2026 financial results, highlighting the successful closing of the Oratech acquisition and a $10 million financing, alongside a 33% reduction in operating cash burn year-over-year.

Lifeward Ltd. reports the termination of Vice President of Strategy and Market Access, Jeannine Lynch, effective May 3, 2026, with severance to be provided as per her employment agreement.

Lifeward Ltd. announced it has regained compliance with Nasdaq's audit committee requirements following new appointments to its board.

Lifeward Ltd. announced the completion of its acquisition of Oratech Pharma, Inc., alongside significant board changes and equity issuance.

Lifeward Ltd. received a Nasdaq notice for non-compliance with audit committee requirements following a director's resignation, but its shares continue to trade.

Lifeward Ltd. reported a 6.4% revenue decrease for the nine months ended September 30, 2025, but improved gross profit margins and reduced operating cash burn, while facing a Nasdaq delisting notice and securing a $3.0 million loan.

Lifeward Ltd. reported increased net losses and a going concern warning for Q2 2025, despite significant capital raises and strategic product advancements.

Lifeward Ltd. reports a decrease in revenue for Q1 2025, alongside ongoing efforts to manage financial stability and expand market reach.

Lifeward Ltd. saw a significant increase in revenue in the third quarter of 2024, driven by expanded Medicare coverage and the integration of AlterG, while also announcing a streamlining of US operations.

Lifeward, formerly ReWalk Robotics, saw a significant increase in revenue in the second quarter of 2024, driven by the acquisition of AlterG and expanded Medicare coverage for its ReWalk Personal Exoskeleton.

Lifeward, formerly ReWalk Robotics, saw a 340% increase in revenue in Q1 2024 compared to Q1 2023, driven by the acquisition of AlterG and positive changes in Medicare reimbursement policies.

Lifeward Ltd. reported a 14% revenue decrease to $22.0 million in 2025, alongside a reduced net loss, but acknowledged substantial doubt about its ability to continue as a going concern.

Lifeward Ltd. releases its 10-K filing, highlighting revenue growth driven by the AlterG acquisition and Medicare coverage, while also acknowledging substantial doubt about its ability to continue as a going concern.

ReWalk Robotics has filed an amendment to its 2023 annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Lifeward, formerly ReWalk Robotics, announced record annual revenue of $13.9 million for 2023, driven by the acquisition of AlterG and positive developments in Medicare coverage for exoskeletons.

Lifeward Ltd. Chief Medical Officer Keith Dale reports acquisition of 15,000 ordinary shares via vesting of restricted stock units.

Lifeward Ltd. Director William Mark Sigsbee acquired 11,485 ordinary shares through the vesting of restricted stock units.

Moshe H. Rozenbaum, a Director at Lifeward Ltd., reported the acquisition of 11,485 ordinary shares through the vesting of restricted stock units.

Lifeward Ltd.'s Chief Financial Officer, Almog Adar, was granted 39,934 stock options with an exercise price of $6.53, vesting over four years.

Lifeward Ltd. President and CEO, William Mark Grant, was granted options to purchase 172,698 ordinary shares at an exercise price of $6.53.

Lifeward Ltd. Director Yehuda Reznick was granted 7,657 restricted stock units, aligning his interests with shareholders.

Lifeward Ltd. will hold an Extraordinary General Meeting on January 6, 2026, to vote on proposals including a reverse share split to maintain its Nasdaq listing and an increase in authorized share capital.

Lifeward Ltd. has issued its definitive proxy statement for the 2025 Annual Meeting, proposing the ratification of its new President and co-Chief Executive Officer's compensation, an increase in authorized share capital to facilitate future financing, and the approval of a new incentive compensation plan, against a backdrop of significant declines in total shareholder return and continued net losses.

Lifeward Ltd. announces the postponement of its Extraordinary General Meeting of Shareholders due to an anticipated lack of quorum, rescheduling it to January 13, 2025.

Lifeward Ltd. has scheduled an Extraordinary General Meeting for December 30, 2024, to vote on proposals including eliminating the par value of ordinary shares and approving a new incentive compensation plan.

ReWalk Robotics successfully defended against a shareholder's legal action seeking to add their director nominees to the agenda of the upcoming Annual Meeting.

ReWalk Robotics is contesting a shareholder's attempt to add their director nominees to the agenda of the upcoming Annual Meeting, leading to a legal dispute.

Lifeward Ltd., a medical device company, has filed an S-1/A registration statement to offer up to 4 million ordinary shares and accompanying warrants, seeking to raise approximately $3.6 million in net proceeds to fund ongoing commercial efforts and general corporate purposes, while acknowledging substantial doubt about its ability to continue as a going concern.

Lifeward Ltd., a medical device company, has filed an S-1 registration statement to offer up to 4,000,000 ordinary shares and warrants, aiming to raise approximately $3.6 million in net proceeds, while acknowledging substantial doubt about its ability to continue as a going concern.

Lifeward Ltd. is filing an amendment to its registration statement for the resale of up to 1.9 million ordinary shares issuable upon the exercise of outstanding warrants.

Lifeward Ltd. is seeking to register the resale of ordinary shares issuable upon the exercise of outstanding warrants, which could generate up to $5.4 million in proceeds for the company.

Oramed Pharmaceuticals has filed a Schedule 13D reporting a 49.9% beneficial ownership stake in Lifeward Ltd. following the acquisition of Oratech Pharma and a private placement of convertible notes.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a passive beneficial ownership of 4.99% in Lifeward Ltd.'s Ordinary Shares as of July 1, 2025.

Lind Global Fund II LP, along with its affiliates, has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 1.7% in Lifeward Ltd.'s ordinary shares as of March 31, 2025.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 4.99% beneficial ownership stake in Lifeward Ltd. ordinary shares, a reduction from a deemed 9.3% due to a warrant blocker provision.

Lind Global Fund II LP, along with its general partner Lind Global Partners II LLC and managing member Jeff Easton, has disclosed a beneficial ownership of 8.9% in Lifeward Ltd., totaling 945,746 ordinary shares.